The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center (CCC) has a long history of participation within the nation's cancer related Clinical Trials Cooperative Group Program. Specifically, UAB was a founding member of the GOG, and has been a member of RTOG, ECOG, ACRIN. CALGB, NSABP, and SWOG. The UAB CCC now submits this proposal to become a Lead Academic Participating Site, specifically named the NCTN Deep South Research Consortium, in the NCI's newly restructured National Clinical Trials Network (NCTN) Program. It is our intention to continue as a leading contributor of scientific leaders and clinical trial participants to the NCTN Program in th U.S. and particularly in the Southeast. To accomplish this overall vision, we propose the following specific aims: 1) To further enhance the involvement of existing UAB CCC scientific leadership in NCTN Center related clinical and translational research and to develop the next generation of NCTN Center scientific leaders within the UAB CCC, and 2) To further refine a clinical trials process within the UAB CCC that optimizes accrual of potentially eligible cancer patients and patients at risk for cancer to NCTN Center clinical trials. We include in this proposa a detailed description of our NCI cooperative group scientific and patient accrual contributions and accomplishments, a leadership and organizational structure for our proposed Consortium, and how we intend to utilize existing UAB CCC infrastructure to achieve our aims. We also include a detailed description of our proposed Junior Investigator Recruitment and Mentoring Program.

Public Health Relevance

This proposal will ensure that the NCTN Program is provided better access to UAB CCC clinical and translational investigators with a broad interest in cancer prevention and control, cancer biology, and experimental therapeutics. Importantly, this proposal will also provide NCTN clinical trials better access to a patient population that based upon its demographics and socioeconomic status is distinct from other areas in the country.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
Obstetrics & Gynecology
Schools of Medicine
United States
Zip Code
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2016) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv :
Miller, Caela R; Chappell, Nicole P; Sledge, Caitlin et al. (2016) Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? Gynecol Oncol :
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2016) Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Res :
Bar-Ad, Voichita; Zhang, Qiang Ed; Harari, Paul M et al. (2016) Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. Int J Radiat Oncol Biol Phys 95:1346-54
Niederwieser, Christian; Nicolet, Deedra; Carroll, Andrew J et al. (2016) Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica 101:1516-1523
Othus, Megan; van Putten, Wim; Lowenberg, Bob et al. (2016) Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. Haematologica 101:e284-6
Hylton, Nola M; Gatsonis, Constantine A; Rosen, Mark A et al. (2016) Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 279:44-55
Alvarez, Ronald D (2016) Report on NRG Oncology and the GOG Foundation. Gynecol Oncol 140:381-2
Othus, M; Wood, B L; Stirewalt, D L et al. (2016) Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia 30:2080-2083
Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :

Showing the most recent 10 out of 36 publications